Richard Griffiths (SLN) reports 14.39M-share beneficial stake in Silence Therapeutics
Richard Griffiths filed Amendment No. 11 reporting beneficial ownership of 14,391,498 Silence Therapeutics plc ordinary shares, or 7.97% of the class, based on 180,628,068 shares outstanding. Holdings include ADSs via Ora Capital Limited and Cream Capital Limited plus direct shares. The filing cites dilution from share capital increases and open-market ADS sales, including 5,484,320 ADSs sold Aug 10-12, 2026 for $87 proceeds.
How this was made
The 30-second read
Why it matters
The key new information is the updated beneficial stake (14,391,498 ordinary shares, 7.97%) and the stated drivers: dilution from increased share capital plus open-market ADS sales between Aug 10 and Aug 12, 2026.
Market read
A major holder’s updated stake and disclosed ADS sales can influence short-term positioning, but the filing does not introduce new operational or clinical developments.
What to watch
The filing does not quantify whether the holder’s economic exposure changed materially beyond the reported beneficial ownership; traders should check whether dilution was driven by financing terms that could also be supportive or dilutive.
Background
The article summarizes an SEC-style beneficial ownership amendment (Amendment No. 11) by Richard Griffiths for Silence Therapeutics plc.
Ticker impact
Richard Griffiths filed an Amendment No. 11 showing beneficial ownership of 14,391,498 shares, citing dilution and ADS sales Aug 10-12.
Low to modest negative bias possible if investors interpret the sales as reduced conviction, but the filing is not a company fundamental update.
The article provides specific stake size (7.97%) and the reason (dilution plus ADS sales), but it does not include new company performance, guidance, or regulatory/clinical catalysts.
Market effects
Limited read-through to biotech/therapeutics sector; this is a single-holder disclosure rather than a sector-wide catalyst.
No clear regional market linkage beyond potential sentiment for the issuer.
Minimal global relevance; ownership/dilution disclosure is company-specific.
Counterpoint
The disclosed ADS sales may be routine liquidity management rather than a bearish signal, especially since the filing emphasizes dilution from share capital increases.
Key entities
- issuerSilence Therapeutics plc
The company whose ordinary shares and ADSs are covered by the beneficial ownership amendment.
- insider_or_major_holderRichard Griffiths
Reported beneficial owner updating holdings and disclosing ADS sales and dilution context.
- holder_entityOra Capital Limited
Holds 10,777,044 shares represented by ADSs as part of Griffiths’ beneficial ownership structure.
- holder_entityCream Capital Limited
Holds 600,000 shares represented by ADSs as part of Griffiths’ beneficial ownership structure.
